“the miroial halle nge towards a global research agenda ...€¦ · towards a global research...

Official Launch of the JPIAMR Strategic Research Agenda “THE MICROBIAL CHALLENGE –

AN EMERGING THREAT TO HUMAN / ANIMAL HEALTH

Towards a Global Research Agenda for AMR

OBJECTIVES

To achieve wide recognition and awareness for the findings and roadmap of the JPIAMR Strategic Research Agenda (SRA)

To encourage uptake of the recommendations developed in the SRA by a wide range of stakeholders

To encourage a follow-up and future collaboration between research funding agencies in the field of Antimicrobial Resistance

To encourage the participation of private funders

To discuss among international partner funders of key priorities of the SRA and what is relevant for them by developing global funding opportunities

To work towards a global Joint Programming Initiative

3 April 2014 |Brussels|Belgium

De Warande Room Salon Lode Baron Campo|Zinnerstraat 1|1000 Brussels

Official Launch event of the JPIAMR Strategic Research Agenda

PROGRAMME

Thursday April 3 2014

Opening session

Moderator/Introducer: Fulvio Esposito, Chair GPC and Head of Technical Secretariat of the Minister for Education, University and Research, Italy

09.30 Welcome Address │ Lena Furmark │ State Secretary, Ministry of Health and Social Affairs, Sweden

09.45 Welcome Address │ Máire Geoghegan-Quinn │ European Commissioner for Research, Innovation and Science (recorded video)

10.10 Why is AMR a human threat? │Carmem Pessoa │ Head of the AMR unit, World Health Organization

10.30 Why a Joint Programming Initiative on AMR │ Mats Ulfendahl │ MB Chair, Swedish Research Council

10.50 COFFEE BREAK – Salon Lode Baron Campo

SRA Presentation session: The JPIAMR Strategic Research Agenda

Moderator: Bertrand Schwartz (ANR) and Laurent Gutmann Head of microbiological Laboratory at the

European Hospital Georges Pompidou, INSERM, France

11.20 The JPIAMR Strategic Research Agenda│ Herman Goossens │ SAB Chair, University of Antwerp

11.45 The UK strategy for antimicrobial resistance (AMR) and its implications for research and development|

John Watson|Deputy Chief Medical Officer at the Department of Health, United Kingdom

12.10 Reflections on the SRA from the industry point of view │ Richard Bergström │ Director, EFPIA

12.35 Open discussion

60 min Lunch Break

Session 1: Funding of AMR programmes

Moderator: André Van der Zande, Director-General at RIVM, The Netherlands

Scope:

Presentation mapping analysis on AMR funding

Presentation of AMR funding schemes by countries

Questions for the presentations:

Which are the common denominators of funding schemes

Areas for coordination/collaboration: gap analysis

Opportunities for global funding initiatives: Which is the type of research that needs to be

funded at a global level?

14.00 Funding AMR research: the British approach│ Sir John Savill| Chief Executive of the Medical Research Council,

United Kingdom


14.15

NIH´s antibacterial resistance program| Dennis M. Dixon|Chief, Bacteriology and Mycology Branch, National

Institute of Allergy and Infectious Diseases, NIH, USA

14.30

14.45

The South African perspective on the antimicrobial resistance challenge| Niresh Bhagwandin| Executive

Manager: Strategic Research Initiatives, South African Medical Research Council

Antimicrobial resistance; the Canadian perspective| Alain Beaudet| President, Canadian Institutes of Health

Research, Canada

15.00

15.30

Debate: Gaps and needs | Debate: Relationships with public funding

COFFEE BREAK – Salon Lode Baron Campo

Session 2: Implementing the SRA: opportunities for global funding

Moderator: Marc Ouellette, Scientific Director, Canadian Institutes of Health Research, Canada

Scope:

Presentation of AMR funding schemes by countries/agencies by SRA topics that needs a global

action

Questions for the presentations:

Which are the common denominators of funding schemes

Areas for coordination/collaboration: gap analysis

Opportunities for global funding initiatives: Which is the type of research that needs to be

funded at a global level?

16.00 Australia’s response to the threat of antimicrobial resistance|Warwick Anderson| Chief Executive Officer,

National Health & Medical Research Council, Australia (recorded video)

16.15

16.30

Policies and challenges for control of AMR in India| Jayaraman Gowrishankar| Centre for DNA Fingerprinting

and Diagnostics Department of Biotechnology, Ministry of Science and Technology, Government of India

Building a public national system for antimicrobial resistance surveillance in Argentina|

Marcelo Galas| Director, National Institute for Infectious Diseases, Argentina

16.45 Research going global – the EC´s readiness to lead the fight against AMR| Line Matthiessen| Head of Unit,

Infectious Diseases and Public Health Unit, DG Research and Innovation, European Commission

17.00 Open discussion and concluding remarks: presentation of Statement on AMR

18.00 Cocktail reception


Lena Furmark, R NM. Sc. State Secretary, Ministry of Health and Social Affairs, Sweden

Mrs Furmark started her professional career as a Registered Nurse in 1980. She holds a Bachelor Degree in Political Science and Economics, a Degree in Common Law and a Degree in Healthcare Administration.Before joining the Ministry in 2010 Lena Furmark was the CEO of Caritea, a Swedish consultancy company focusing on business intelligence and healthcare change management.

Between 2002 and 2008, Mrs Furmark worked for Microsoft Corporation as Healthcare Business Development Manager in Sweden and Western Europe. Before that she was employed by the Federation of the County Councils in Sweden where she served as Director of the Executive Board Office. Mrs Furmark has also served as Director of Office in the Swedish Parliament and has had several expert- and consultancy assignments in Swedish parliamentary commissions and for the UN. Lena Furmark has served as a member of several boards i e Swedish Red Cross, Systembolaget, the Swedish Alcohol Retail Monopoly, and Swedish Pharmacy International Inc. She also has been the Chair of the Project Steering Board of the EpSOS project. www.epsos.eu

Máire Geoghegan-QuinnEuropean Commissioner for Research, Innovation and Science

Máire Geoghegan-Quinn has been the European Commissioner for Research, Innovation and Science since 2010. Between 2000 and 2010, she served as a Member of the Eropean Court of Auditors. From 1975 to 1997, she was a Member of the Irish parliament (Dáil Eireann). In 1979, she became the first woman to be appointed as a Cabinet Minister since the foundation of the Irish state, and served

as Minister with responsibility for the Gaeltacht until 1981. She has held various other ministerial posts, including Minister for European Union Affairs from 1987 to 1991, when she oversaw the preparation of the Irish presidency of the European Union in 1990; Minister for Tourism, Transport and Communications (1992-’93). She was the Irish Minister for Justice (1993-’94) and one of the negotiators of the Downing Street Declaration, which was signed between the Irish and British governments. From 1997 to 2000, Máire Geoghegan-Quinn served as Non-Executive Director of both Aer Lingus and the Ryan Hotel Group. She has been a TV presenter and a columnist in the Irish Times newspaper, and is a former Member of the Governing Authority of the National University of Ireland Galway.

Carmem PessoaHead of the AMR unit, World Health Organisation, Switzerland

Dr Carmem L. PESSOA-SILVA, MD, PhD, is Brazilian, joined the World Health Organization (WHO) in 2005. From January 2005 to November 2011 Dr Pessoa-Silva was the Team Leader for the WHO programme “Infection Prevention and Control in Health Care”. In the context of renewed efforts to combat antimicrobial drug resistance, WHO established the programme “Antimicrobial Drug Resistance”

in December 2011 and appointed Dr Pessoa-Silva to lead the new programme. Prior to WHO, Dr Pessoa-Silva gathered 20 years of professional experience as an infectious diseases physician in Brazil where she is an Associate Professor of Medicine at the Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

SPEAKERS´ BIOGRAPHIES


Mats UlfendahlSecretary-General, Swedish Research Council, Sweden

Mats Ulfendahl (born 1959) is Secretary-General for medicine and health at the Swedish Research Council, and a member of the Council’s management team. He received his doctorate in physiology at Karolinska Institutet in 1989. In 2004 he was appointed professor of experimental audiology and otology (Karolinska Institutet). Dr. Ulfendahl was director of the Center for Hearing and Communication

Research from 2002 to 2010 when he was appointed Secretary-General. He serves on several national boards, including the board of The Swedish Council on Technology Assessment in Health Care and the National priority board for highly specialized health care. Dr. Ulfendahl was recently re-elected as Chair of the management board of JPIAMR, and he is the Swedish representative on the management board of JPND (Joint Programming on Neurodegenerative Disease Research). Dr. Ulfendahl is a member of the Governing Council of International Agency for Research on Cancer (IARC), Heads of International Research Organizations, and the High Level Group for Joint Programming (GPC).

Herman GoossensSAB Chair, University of Antwerp, Belgium

Herman Goossens is a professor of Medical Microbiology at the University of Antwerp in Belgium and the director of the Laboratory of Clinical Pathology of the University Hospital Antwerp. He received several honours and awards, including the American APUA (Alliance for the Prudent Use of Antibiotics) award in 2006. Herman Goossens published more than 450 full papers in peer-reviewed scientific

journals. He is the founder and Vice-Chair of the Belgian Antibiotic Policy Co-ordination Committee (BAPCOC). He coordinates several European projects funded by DG Research, DG SANCO, IMI and ECDC, such as Development of RApid Point-of-care test Platforms for Infectious Diseases (RAPP-ID), Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE), and LAB-Net of the Combating Bacterial Resistance in Europe project (COMBACTE). Herman Goossens was the organiser of the European Conference on Antibiotic Use in 2001 and of the European Conference on Health Care Associated Infections and Antibiotic Use in 2010, both on behalf of the Belgian EU Presidency. He is the founder of the annual European Antibiotic Resistance Day (EAAD) and chairs the Technical Advisory Committee at ECDC for EAAD. Herman Goossens was elected chair of the Scientific Advisory Board of the Joint Programming Initiative on Antimicrobial Resistance.

John WatsonDeputy Chief Medical Officer at the Department of Health, United Kingdom

Professor John Watson MB BS, MSc, FRCP, FFPH - is Deputy Chief Medical Officer for England and based at the Department of Health in London. He was previously a Consultant Clinical Epidemiologist and Head of the Respiratory Diseases Department at Public Health England’s Centre for Infectious Disease Surveillance and Control in London. He is an Honorary Professor in the Faculty

of Epidemiology and Public Health at the London School of Hygiene and Tropical Medicine and Visiting Professor in the Research Department of Infection and Population Health at University College London. He qualified from St Bartholomew’s Hospital Medical School, London, in 1979 and subsequently trained in clinical respiratory medicine and infectious disease epidemiology. His responsibilities span health protection with a particular focus on anti-microbial resistance, immunisation policy and emergency preparedness and response. His previous work focussed on the surveillance, prevention and control of tuberculosis and acute respiratory infections (particularly influenza, legionnaires disease and SARS) at the local, national and international levels as well as related research. He was a founder member in 2005, and Chairman from 2009 to 2013, of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV).


Richard BergströmDirector, EFPIA, Belgium

Richard Bergström has been the Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) since April 2011. Previously he served for nine years as the Director-General of LIF, the Swedish Association of the Pharmaceutical Industry, following positions in Switzerland in regulatory affairs at the pharmaceutical companies Roche and Novartis. Mr Bergström was also appointed by the

Swedish Government to the Board of the Karolinska Institute. He is a pharmacist by training, receiving his MScPharm degree from the University of Uppsala, Sweden in 1988.

Sir John SavillChief Executive of the Medical Reearch Council, United Kingdom

Professor Sir John Savill BA, MBChB, PhD, FRCP, FRCPE, FASN, FMedSci, FRSE, FRS, a clinician scientist from Edinburgh, took up the position as chief executive and deputy chair of the Medical Research Council (MRC) on 1 October 2010. He was a member of the MRC Council from 2002 to 2008 and chaired two MRC Research Boards during this period. Between 2008 and 2010 John worked part-time as the chief scientist for the

Scottish Government Health Directorates. He was knighted in the 2008 New Year’s Honours List for services to clinical science. John started his research career with a degree in Physiological Sciences from Oxford University in 1978, followed by degrees in Medicine at the University of Sheffield in 1981. He received a PhD from the University of London in 1989. After junior hospital appointments in Sheffield, Nottingham and London, he spent seven years in the Department of Medicine at Hammersmith Hospital with spells as an MRC clinical training fellow and Wellcome Trust senior clinical research fellow. In 1993, he moved to the chair of Medicine, at the University of Nottingham, then in 1998 became professor of Medicine at the University of Edinburgh, where he was the first director of the University of Edinburgh/MRC Centre for Inflammation Research, directing a group interested in the molecular cell biology of renal inflammation. In 2002, John was appointed as the first vice-principal and head of the College of Medicine and Veterinary Medicine, University of Edinburgh. He retains an ongoing, research active involvement with the University of Edinburgh part-time throughout his appointment as MRC chief executive.

Dennis M. DixonChief, Bacteriology and Mycology Branch, National Institute of Allergy and Infectious Diseases, NIH, USA

Dr. Dixon is Chief of the Bacteriology and Mycology Branch of the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Focus areas include antimicrobial resistance, health care associated infections, vector borne and zoonotic bacterial diseases, and fungal

diseases. Goals are to address public health needs through research that will improve diagnosis, prevention or treatment. Dr. Dixon serves on numerous federal advisory panels on Select Agents, the National Science Advisory Board for Biosecurity in various capacities, and the domestic and international Task Force on Antimicrobial Resistance. He received his doctorate in microbiology from the Medical College of Virginia in 1978. He held academic positions at Loyola College in Baltimore, the University of Maryland Medical School and Albany Medical College. He served as a Visiting Scientist at Hoffman LaRoche in Switzerland, and as Director for the Mycology Reference Laboratory at the New York State Department of Health. He is a member of the American Academy of Microbiology.


Niresh BhagwandinExecutive Manager: Strategic Research Initiatives, South African Medical Research Council, South Africa

Niresh Bhagwandin has a PhD in Biomedical Engineering from the University of Cape Town and an MBA in Health Planning and Management from Keele University, UK. He is currently Executive Manager: Strategic Research Initiatives at the South African Medical Research Council (MRC) and a member of the MRC

Executive Management Committee. He also serves as the health, demographic change and wellbeing South African National Contact Point for the European Union Horizon 2020 programme.

Alain BeaudetPresident, Canadian Institutes of Health Research, Canada

Dr. Alain Beaudet, MD, PhD. is the President of the Canadian Institutes of Health Research (CIHR) since July 2008. Previously, he was the President and CEO of the Fonds de la recherche en santé du Québec (FRSQ).Among his many accomplishments, Dr. Beaudet was associate director (research) at the Montreal Neurological Institute (MNI). He was also Professor at McGill

University’s Neurology-Neurosurgery and Anatomy-Cell Biology departments. He has authored over 175 original articles and 40 monographs and book chapters. Dr. Beaudet has received numerous distinctions and awards, including two honoris causa doctorate degrees. He is a member of the National Order of Quebec and a Fellow of the Royal Society of Canada. Dr. Beaudet earned a medical degree and a PhD in neuroscience from the Université de Montréal. He completed his postdoctoral training in France and Switzerland. His career as a neuroscientist spanned from Neuroendocrinology to Pain, with a focus of the mechanisms of action of biogenic amines and neuropeptides in the brain.

Warwick AndersonChief Executive Officer, Ntional Health & Medical Research Council, Australia

Professor Warwick Anderson is the Chief Executive Officer (CEO) of NHMRC, Australia’s major governmental funding body for health and medical research. Previously, he was Head of School of Biomedical Sciences at Monash University and Deputy Director of the Baker Medical Research Institute, following research fellowships at the University of Sydney and Harvard Medical School.Professor

Anderson obtained his PhD from the University of Adelaide. His research has focused on renal causes of hypertension, including the roles of renal vascular remodeling, renal innervation and the renin-angiotensin system. He has published over 170 peer review articles.Professor Anderson is a member of the Prime Minister’s Science Engineering and Innovation Council, a Board member of the Global Alliance for Chronic Disease, a member of Heads of International (Biomedical) Research Organizations and of the National Lead Clinicians Group. He is an Honorary Fellow of the Royal College of Pathologists of Australasia and an International Fellow of the American Heart Foundation. He was made a Member of the Order of Australia in 2005.

Jayaraman GowrishankarCentre for DNA Fingerprinting and Diagnostics Department of Biotechnology, Ministry of Science and Technology, Government of India, India

Dr Gowrishankar graduated in medicine (1979) from the University of Madras (India) and completed his Ph.D (1983) in microbial genetics from the University of Melbourne (Australia). Since 1983, he has worked in Hyderabad, India as


independent research investigator in E. coli microbiology, until 2000 at the Centre for Cellular and Molecular Biology and thereafter at the Laboratory of Bacterial Genetics in the Centre for DNA Fingerprinting and Diagnostics (CDFD). He has also been Director of CDFD since December 2005. His research interests have included studies on osmoregulation, solute transporters, biology of transposable elements, mutation mechanisms, and transcription-replication interplay. He is an elected Fellow of the Indian Academy of Sciences and of the Indian National Science Academy, and recipient of the American Society for Microbiology’s Moselio Schaechter Award for Distinguished Service.

Marcelo GalasDirector, National Institute for Infectious Diseases, Argentina

Dr. Galas, Chief of Bacteriology Department at the National Institute of Infectious Diseases, is the General Coordinator of the Bacteriology Laboratory Networks System This system include the following national thematic surveillance networks: Bacterial Meningitis and Respiratory Tract Infections, Diarrhoea and Food Transmited Infections, Sexualy Transmited Infections, Brucella Infections,

Tuberculosis Infections and the WHONET-Argentina network for Antimicrobial Resistance Surveillance. He also is the manager of the last thematic network. At the Malbrán Institute, Dr. Galas has specialized in antimicrobial resistance, especially in clinical diagnosis, characterization of mechanisms of action and resistance, and surveillance. One of his greatest contributions was improving the quality of clinical diagnostic services in Argentina, including establishment of a national program of external quality assessment. Quality indicators over the past 15 years have demonstrated a decrease in diagnostic errors from over 10% to less than 1%. Dr. Galas has collaborated with the Pan American Health Organization to introduce this successful model to nearly all Institutes of Health in Latin America. Currently Dr. Galas is responsible for the coordination and integration of all bacteriological networks of the National Institute of Infectious Diseases orientated to the improvement of clinical diagnosis in health centers, introduction of molecular diagnostic methodologies, characterization of human pathogens and the detection and characterization of both hospital and community outbreaks. The introduction of new diagnostic methods with extensive training of laboratory professionals has improved the accuracy of diagnostic laboratories across the country. Areas of expertise include clinical and molecular aspects of infectious diseases and antimicrobial resistance, building capacity for bacteriological diagnostic, surveillance and quality assurance management.

Line MatthiessenHead of Unit, Infectious Diseases and Global EpidemicsDirectorate E – Health, DG Research & Innovation, European Commission

Dr Line Matthiessen leads the Unit responsible for Infectious Diseases and Public Health in the Directorate-General for Research and Innovation. The Unit promotes and supports EU research and innovation activities in the area of global health issues with emphasis on HIV/AIDS, malaria and tuberculosis, emerging epidemics,

neglected infectious diseases and antimicrobial drug resistance, as well as activities in public health and health systems research. The Unit also supports the implementation of the European and Developing Countries Clinical Trials Partnership (EDCTP). Dr Matthiessen was Head of Unit for horizontal aspects and coordination in the Directorate for Biotechnologies, Agriculture and Food Research from 1 July 2007 to December 2010. Dr Matthiessen joined the European Commission in 1992. She has been responsible for strategic and policy issues in biotechnology. She held the position as principal scientific officer responsible for research in Neurosciences for several years. She has also been scientific officer in the area of Somatic gene therapy, Animal cell technology and in vitro testing as alternatives to animal experiments. Dr Line Matthiessen was trained as an MD at the University of Odense, Denmark and received her PhD in Neurosciences from the University of Paris VI, France in 1993.


MODERATORS

Fulvio EspositoChair GPC and Head of Technical Secretariat of the Minister for Education, University and Research, Italy

Born in Viareggio (Italy) in 1951, full professor of Parasitology at Camerino University (UNICAM) since 1987, Fulvio Esposito developed his scientific background in Pisa University and Scuola Normale Superiore, where he obtained his MSc and PhD in Biology, respectively. His scientific contributions on

various aspects of malaria include immunology and immunotechniques, epidemiology and control, parasitology, entomology. The results he obtained with insecticide-treated netting on child mortality prompted the World Health Organization to adopt and promote this malaria control strategy in endemic countries, particularly in Africa. Some of the doctoral candidates he supervised are now among the leading African scientists, awarded with prestigious international prizes. In UNICAM, he has been the Dean of the Faculty of Science & Technology (1998 – 04) and Rector (2004 – 11).He is collaborating as an expert with the European Commission and representing Italy on subjects related to researchers and research, as member of the ‘Steering Group on Human Resources and Mobility’, and has been elected as Chair of the ‘High level group on Joint Programming of European Research (GPC)’. From July 2013 to February 2014, he has headed the Technical Secretariat of the Minister for Education, University and Research.

Laurent GutmannHead of microbiological Laboratory at the European Hospital Georges Pompidou, France

Laurent Gutmann is MD-PhD .Professor of Microbiology, Head of microbiological Laboratory at the European Hospital Georges Pompidou in Paris, He was Head of Reference Center for Pneumococci (France 1999-2011). He is part of an INSERM research unit [UMRS 872] working on the molecular basis of the resistance to

antibiotics oriented towards the cell wall targets. He was counsellor of the INSERM director for infectious diseases and microbiology. He is presently member of the scientific board of the French thematic institute IMMI (Microbiology and infectious diseases) and member of the JPI-AMR management board.

André Van der ZandeDirector-General at RIVM, The Netherlands

Prof. Dr André van der Zande, PhD (1952) is Director-General at RIVM. He has held this position since 1 January 2011. ”Committed to health and sustainability”. André van der Zande studied biology at Leiden University and graduated with distinction in 1976. In 1984 he was awarded his PhD from the same university on the subject of the field of tension between recreation and bird conservation.

From 1986 onwards he managed various large knowledge institutes in Wageningen, among them Alterra. In addition he was a part-time professor of Spatial Planning and Cultural History under the Belvedère programme at Wageningen University (2005-2009). In 2002 André Van der Zande made the changeover to the former Dutch Ministry of Agriculture, Nature and Food Quality (ministerie van Landbouw, Natuur en Voedselkwaliteit - LNV). Until 2007 he was Director-General at the LNV and his responsibilities included agricultural policy, nature and biodiversity, manure policy and general environmental policy. In 2007 he became Secretary-General there, until the merger of the LNV with the Dutch Ministry of Economic Affairs.


Marc OueletteScientific Director, Canadian Institutes of Health Research, Canada

Dr. Ouellette is the Scientific Director of the Institute of Infectious Disease and Immunity of CIHR since January 1st, 2010. In this capacity, he has led the conception and implementation of several research initiatives in the areas of organ transplantation, inflammation, microbiome, vaccines and antibiotic resistance. Dr. Ouellette also oversees the development and outcomes of the HIV/AIDS

and Hepatitis C Research Initiatives.Dr. Ouellette obtained his Bachelor of Science (Honours) in Biochemistry at Ottawa University and received his PhD at Laval University on antibiotic resistance in bacteria. His postdoctoral studies were done under the mentorship of Pr. Piet Borst of the Netherlands Cancer Institute in Amsterdam, where he further developed his expertise in antimicrobial resistance studying protozoan parasites. In 1990 he joined the Centre de Recherche en Infectiologie, of Laval University as an Assistant professor and is now full professor. Dr. Ouellette’s research is focused on antimicrobial resistance where he has made seminal discoveries on resistance mechanism in protozoan parasites. More recently he has implemented proteomic and DNA microarray strategies to study antimicrobial resistance in the parasite Leishmania and the bacteria Streptococcus pneumoniae.Dr. Ouellette has received numerous awards for his work including a New Investigator Award in Molecular Parasitology from the Burroughs Wellcome Fund, a MRC Scientist Award, a Scholar Award in Molecular Parasitology of the Burroughs Wellcome Fund, and a Tier 1 Canada Research Chair in Antimicrobial Resistance. He is a Fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences. He has served on numerous panels of national and international granting agencies and is a strong supporter of scientific exchanges with developing countries.


LIST OF PARTICIPANTS

Herman Goossens

Richard Bergström

University of Antwerp, Belgium EFPIA

[email protected] [email protected]

Dennis M. Dixon Carmem Pessoa

National Institute of Allergy and Infectious Diseases, USA World Health Organisation


Marc Ouellette Alain Beaudet

Canadian Institutes of Health Research, Canada Canadian Institutes of Health Research, Canada


Marcelo Galas Mats Ulfendahl

National Institute for Infectious Diseases, Argentina Swedish Research Council, Sweden


Niresh Bhagwandin Line Matthiessen

South African Medical Research Council, South Africa European Commission


Jayaraman Gowrishankar Fulvio Esposito

Government of India University of Camerino, Norway


Lena Furmark Karl-Olaf Wathne

Ministry of Health and Social Affairs, Sweden Ministry of Health and Care Services, Norway


Sir John Savill Lene Cividanes

Medical Research Council, United Kingdom The Danish Council for Strategic Research, Denmark


John Watson Gloria Villar

Department of Health, United Kingdom Instituto de Salud Carlos III, Spain


Antoine Andremont Sally Donaldson

Hôpital Bichat-Claude Bernard, France ERC


mailto:[email protected]












Jane Knisely

Martijntje Bakker

National Institute of Allergy and Infectious Diseases, USA ZonMW, The Netherlands


Bertrand Schwartz Ayse Özge Gozay

ANR (National Agency for Research), France TUBITAK, Turkey

[email protected]

[email protected]

Laurent Gutmann Jaana Vuopio

Inserm/Aviesan, France Academy of Finland, Finland


Andreas Aeschlimann Ahmi Ben-Yehudah

Federal Department of Economic Affairs, Switzerland Ministry of Health, Israel


Anita Janelm Hajo Grundmann

Social Ministry, Sweden UMCG, Groningen, The Netherlands


Niels Frimodt-Møller Luis Valente

Statens Serum Institut, Denmark FCT, Portugal


Mattias Norrby Desmond Walsh

Formas, Sweden Medical Research Council, United Kingdom


Dunja Dreesens Ghada Zoubiane

ZonMW, The Netherlands Medical Research Council, United Kingdom


Waleria Hryniewicz Ewa Sadowy

National Medicines Institute, Poland National Medicines Institute, Poland


Bülent Genc Arjon van Hengel

Forschungszentrum Jülich GmbH, Germany European Commission











Bruno Gonzalez-Zorn

Jan Vaarten

Universidad Complutense de Madrid, Spain Federation of Veterinarians of Europé, Belgium


Danilo Lo Fo Wong Ceyssens Pieter-Jan

World Health Organization, Denmark Scientific Institute of Public Health, Belgium


Andreas Krell Magda Chlebus

Europ. Liaison Office of the German Research Org., Belgium EFPIA


Remko van Leeuwen S.A.J. Zaat

AIGHD, The Netherlands Academic Medical Center, The Netherlands


Constance Schultsz Robin Moudy

University of Amsterdam, The Netherlands AAAS S&T Policy Fellow


Maurice Samuel Devaraj Seamus O'Brien

India AstraZeneca, United Kingdom


Judith Hackett Hubert P ENDTZ

Astrazeneca, Inc., USA Fondation Mérieux, France


Mathias Winterhalter Patricia Paukovits

Jacobs University Bremen (BTW: IMI-Topic 2), Germany European Commission DG RTD


Anders Karlén Jean-Charles Cavitte

Uppsala University, Sweden European Commission


Carlos Arauzo Burillo Xavier Daura

European Commission DG RTD/F3 Universitat Autònoma de Barcelona, Spain


Miguel Vicente Alana Yuill

Centro Nacional de Biotecnología-CSIC, Spain Canadian Institutes of Health Research, Canada





Philippe Kagan

Thomas Allvin

EIE, France Permanent Repr. of Sweden to the EU, Sweden


Liselotte De Vos Laura Marin

Departement EWI, Flemish Government, Sweden Swedish Research Council, Sweden


Ruth Kelly Paul Williams

MRC/ JPIAMR, United Kingdom University of Nottingham, United Kingdom


Tim Walsh Sofia Kuhn

Cardiff University, United Kingdom Muninn Science Communication, Belgium


Pontus Holm Cecilia Mattsson

Swedish Research Council, Sweden Swedish Research Council, Sweden


Mikaela Laine Paola Norlin

Swedish Research Council, Sweden Swedish Research Council, Sweden


Jenny Maukola Gazelle Gaignaire

Research Europé, United Kingdom e-gazelle, Belgium


André Van der Zande Giorgio Clarotti

RIVM European Commission


Richard Bax Carsten Strøby Jensen

Transcrip-partners.com, Belgium University of Copenhagen, Denmark


Gregoire Tallard Martin Steinbakk

OECD, France Norwegian Institute for Public Health, Norway


Tim Walsh

Cardiff University

[email protected] ©Photo: Photography cover: Cover by Shutterstock, Mikael Damkier, Edwin Verin, Molecule mureidomycin A via E.Ruijter, cow via J.Wagenaar, medical specialists via S. Geerlings, petri dish via D. Mevius.










“the miroial halle nge towards a global research agenda ...€¦ · towards a global research...

Documents